Pharmaceutical - Markets & Marketing, Diabetes

Filter

Popular Filters

1 to 25 of 57 results

Novo Nordisk and Roche Diabetes Care launch new treatment option

Novo Nordisk and Roche Diabetes Care launch new treatment option

03-11-2014

Danish diabetes care giant Novo Nordisk has today launched NovoRapid PumpCart, the first pre-filled pump…

DiabetesMarkets & MarketingNovo NordiskNovoRapidPharmaceuticalRocheSwitzerland

Boehringer Ingelheim and Lilly revise diabetes alliance in certain countries

29-10-2014

In a move that will strengthen their 2011 alliance by enhancing efficiencies and enabling greater focus…

Boehringer IngelheimDiabetesEli LillyJardianceJentaduetoLicensingMarkets & MarketingPharmaceuticalTrajenta

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

Ultra-rapid-acting insulin formulations will revolutionize type 1 diabetes market by 2019

08-10-2014

Ultra-rapid formulations of the currently marketed rapid-acting insulin analogs have the clear potential…

AdociaBioChaperoneDiabetesFIAspGlobalMarkets & MarketingNovo NordiskPharmaceuticalResearch

Mexico first country to launch Novo Nordisk’s Ryzodeg

Mexico first country to launch Novo Nordisk’s Ryzodeg

01-09-2014

Danish diabetes care giant Novo Nordisk today announced that Mexico has become the first country in the…

DiabetesMarkets & MarketingMexicoNovo NordiskPharmaceuticalRyzodeg

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

Lilly and Boehringer closing in on diabetes market lead with Jardiance approval

07-08-2014

With the recent approval of Jardiance (empagliflozin) in the USA, Eli Lilly and its partner, German family-owned…

Boehringer IngelheimDiabetesEli LillyEli Lilly and CompanyJanuviaJardianceMarkets & MarketingMerck & CoPharmaceuticalTradjenta

Existing diabetes drug Victoza could be effective treatment for world’s obese

Existing diabetes drug Victoza could be effective treatment for world’s obese

06-08-2014

Pharmaceutical companies are racing to find a new form of obesity drug as patient numbers spiral and…

Anti-diabetic drugsDiabetesGastro-intestinalsGlobalMarkets & MarketingNovo NordiskPeptide hormonesPharmaceuticalVictoza

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

07-07-2014

Danish diabetes care giant Novo Nordisk's fixed-dose combination therapy insulin degludec/liraglutide…

DiabetesEuropeIDegLiraMarkets & MarketingNovo NordiskPharmaceuticalUSAXultophy

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

19-06-2014

Danish diabetes care giant Novo Nordisk has launched its newest prefilled insulin delivery device Levemir…

DiabetesLevemirMarkets & MarketingNovo NordiskPharmaceuticalUSA

Global microvascular complications of diabetes market value to almost double by 2022

Global microvascular complications of diabetes market value to almost double by 2022

20-03-2014

The microvascular complications of diabetes pharmaceutical market value in the seven major countries…

AbbVieatrasentanDiabetesGlobalMarkets & MarketingPharmaceutical

Takeda’s new diabetes drug Vipidia debuts in UK

26-02-2014

Japan’s largest drugmaker Takeda Pharmaceuticals this morning launched its new type 2 diabetes drug…

alogliptinDiabetesMarkets & MarketingNorthern EuropePharmaceuticalTakeda PharmaceuticalsUKVipidia

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Diabetes epidemic in China provides lucrative opportunity for anti-diabetic drugs

Diabetes epidemic in China provides lucrative opportunity for anti-diabetic drugs

19-02-2014

The number of people with diabetes in China is set to soar 37% from 118 million to 162 million by 2030,…

ChinaDiabetesMarkets & MarketingPharmaceutical

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Report: Next generation type 2 diabetes drugs create vast opportunities in Europe

Report: Next generation type 2 diabetes drugs create vast opportunities in Europe

11-02-2014

Type 2 diabetes is one of the most significant global health concerns of modern times. According to the…

DiabetesEuropeInsulinMarkets & MarketingPharmaceutical

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

14-12-2013

Drug majors Bristol-Myers Squibb and AstraZeneca have reportedly decided to stop marketing their diabetes…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaMarkets & MarketingPharmaceuticalPricing

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Type 2 diabetes market to reach $38.8 billion by 2019

25-10-2013

The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

DPP-IV inhibitors use in newly-diagnosed type 2 diabetes patients

03-10-2013

Through analysis of US longitudinal patient-level claims data, dipeptidyl peptidase (DPP-IV) inhibitors…

DiabetesMarkets & MarketingNorth AmericaPharmaceutical

Global type 2 diabetes market to reach $38.8 billion by 2019

25-09-2013

The global type 2 diabetes market is expected to grow from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinLG Life SciencesMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

1 to 25 of 57 results

Back to top